​

BridgeBio Pharma (BBIO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

BBIO Stock Forecast

BridgeBio Pharma (BBIO) stock forecast, based on 27 Wall Street analysts, predicts a 12-month average price target of $109.08, with a high of $130.00 and a low of $97.00. This represents a 45.91% increase from the last price of $74.76.

- $30 $60 $90 $120 $150 High: $130 Avg: $109.08 Low: $97 Last Closed Price: $74.76

BBIO Stock Rating

BridgeBio Pharma stock's rating consensus is Buy, based on 27 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 24 Buy (88.89%), 3 Hold (11.11%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 27 0 3 24 Strong Sell Sell Hold Buy Strong Buy

BBIO Price Target Upside V Benchmarks

TypeNameUpside
StockBridgeBio Pharma45.91%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts7937
Avg Price Target$106.71$107.00$98.89
Last Closing Price$74.76$74.76$74.76
Upside/Downside42.74%43.12%32.28%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 265143--22
Aug, 266142--22
Jul, 266162--24
Jun, 266152--23
May, 266161--23
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 01, 2026Mizuho Securities$110.00$76.5943.62%47.14%
Aug 12, 2026Danielle BrillTruist Financial$107.00$83.8927.55%43.12%
Aug 12, 2026Canaccord Genuity$106.00$83.7026.64%41.79%
Aug 11, 2026Josh SchimmerCantor Fitzgerald$110.00$84.7329.82%47.14%
Aug 11, 2026Sean LaamanMorgan Stanley$97.00$84.6714.56%29.75%
Aug 11, 2026Derek ArchilaWells Fargo$102.00$84.6720.47%36.44%
Aug 11, 2026Piper Sandler$115.00$84.6735.82%53.83%
Jul 13, 2026H.C. Wainwright$120.00$85.8939.71%60.51%
Jun 16, 2026Salim SyedMizuho Securities$96.00$68.0041.18%28.41%
Jun 03, 2026Canaccord Genuity$104.00$63.8862.81%39.11%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 02, 2026UBSBuyBuyhold
Aug 12, 2026CitigroupNeutralNeutralhold
Aug 11, 2026Cantor FitzgeraldOverweightOverweighthold
Aug 11, 2026Cowen & Co.BuyBuyhold
Aug 11, 2026Morgan StanleyOverweightOverweighthold
Aug 11, 2026Wells FargoOverweightOverweighthold
Aug 11, 2026Piper SandlerOverweightOverweighthold
Jul 16, 2026CitigroupNeutralNeutralhold
Jul 13, 2026H.C. WainwrightBuyBuyhold
May 28, 2026Morgan StanleyOverweightOverweighthold

Financial Forecast

EPS Forecast

$-10 $-7 $-4 $-1 $2 $5 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.90$-3.35$-3.95$-2.88$-3.78---
Avg Forecast$-3.70$-3.13$-3.76$-2.52$-3.55$-2.51$-0.57$1.91
High Forecast$-1.53$-1.18$-3.60$-2.32$-2.63$-0.86$0.68$4.02
Low Forecast$-9.39$-7.28$-3.97$-2.70$-4.27$-3.28$-0.95$0.30
Surprise %5.41%7.03%5.05%14.29%6.48%---

Revenue Forecast

$0 $700M $1B $2B $3B $4B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$69.72M$77.65M$9.30M$221.90M$362.37M---
Avg Forecast$78.26M$82.75M$12.29M$219.05M$176.98M$437.33M$967.67M$1.67B
High Forecast$170.79M$167.23M$16.09M$230.15M$313.43M$442.24M$1.01B$3.08B
Low Forecast$43.03M$43.07M$7.40M$214.98M$64.02M$432.43M$928.41M$588.98M
Surprise %-10.91%-6.16%-24.31%1.30%104.75%---

Net Income Forecast

$-1B $-600M $-200M $200M $600M $1B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-562.54M$-481.18M$-643.20M$-535.76M$-724.93M---
Avg Forecast$-450.77M$-570.76M$-643.20M$-438.86M$-561.83M$-336.28M$-21.66M$311.59M
High Forecast$-360.62M$-456.61M$-514.56M$-376.93M$-428.14M$-139.25M$110.71M$654.37M
Low Forecast$-540.92M$-684.91M$-771.84M$-439.49M$-695.53M$-533.31M$-154.03M$49.48M
Surprise %24.80%-15.69%-22.08%29.03%---

BBIO Forecast FAQ

Is BridgeBio Pharma stock a buy?

BridgeBio Pharma stock has a consensus rating of Buy, based on 27 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 24 Buy, 3 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that BridgeBio Pharma is a favorable investment for most analysts.

What is BridgeBio Pharma's price target?

BridgeBio Pharma's price target, set by 27 Wall Street analysts, averages $109.08 over the next 12 months. The price target range spans from $97 at the low end to $130 at the high end, suggesting a potential 45.91% change from the previous closing price of $74.76.

How does BridgeBio Pharma stock forecast compare to its benchmarks?

BridgeBio Pharma's stock forecast shows a 45.91% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for BridgeBio Pharma over the past three months?

  • September 2026: 22.73% Strong Buy, 63.64% Buy, 13.64% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 27.27% Strong Buy, 63.64% Buy, 9.09% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 25.00% Strong Buy, 66.67% Buy, 8.33% Hold, 0% Sell, 0% Strong Sell.

What is BridgeBio Pharma’s EPS forecast?

BridgeBio Pharma's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.51, marking a -33.60% decrease from the reported $-3.78 in 2025. Estimates for the following years are $-0.57 in 2027, and $1.91 in 2028.

What is BridgeBio Pharma’s revenue forecast?

BridgeBio Pharma's average annual revenue forecast for its fiscal year ending in December 2026 is $437.33M, reflecting a 20.69% increase from the reported $362.37M in 2025. The forecast for 2027 is $967.67M, and $1.67B for 2028.

What is BridgeBio Pharma’s net income forecast?

BridgeBio Pharma's net income forecast for the fiscal year ending in December 2026 stands at $-336M, representing a -53.61% decrease from the reported $-725M in 2025. Projections indicate $-21.661M in 2027, and $311.59M in 2028.